Switch theme
Sign up to access all valuation multiples
Entrada Therapeutics Inc clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. The Company’s Endosomal Escape Vehicle (EEV)-therapeutics are designed to enable the efficient delivery of a wide range of therapeutics into a variety of organs and tissues, resulting in an improved therapeutic index. Its pipeline includes solutions for Neuromuscular Disease, Beyond Neuromuscular, and Platform Expansion.
2016
183
LTM Revenue $161M
LTM EBITDA n/a
-$63.0M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Entrada Therapeutics has a last 12-month revenue of $161M and a last 12-month EBITDA of n/a.
In the most recent fiscal year, Entrada Therapeutics achieved revenue of $211M and an EBITDA of $50.8M.
Entrada Therapeutics expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Entrada Therapeutics valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $129M | $211M | XXX | XXX | XXX |
| Gross Profit | n/a | n/a | XXX | XXX | XXX |
| Gross Margin | NaN% | NaN% | XXX | XXX | XXX |
| EBITDA | -$0.3M | $50.8M | XXX | XXX | XXX |
| EBITDA Margin | 0% | 24% | XXX | XXX | XXX |
| Net Profit | -$94.6M | -$6.7M | XXX | XXX | XXX |
| Net Margin | -73% | -3% | XXX | XXX | XXX |
| Net Debt | n/a | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, Entrada Therapeutics's stock price is $8.
Entrada Therapeutics has current market cap of $298M, and EV of -$63.0M.
See Entrada Therapeutics trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| -$63.0M | $298M | XXX | XXX | XXX | XXX | $0.22 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, Entrada Therapeutics has market cap of $298M and EV of -$63.0M.
Entrada Therapeutics's trades at -0.4x LTM EV/Revenue multiple, and n/a LTM EBITDA.
Analysts estimate Entrada Therapeutics's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Entrada Therapeutics and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | -$63.0M | XXX | XXX | XXX |
| EV/Revenue | -0.3x | XXX | XXX | XXX |
| EV/EBITDA | -1.2x | XXX | XXX | XXX |
| P/E | 4.5x | XXX | XXX | XXX |
| P/E/Growth | n/a | XXX | XXX | XXX |
| EV/FCF | 1.4x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpEntrada Therapeutics's NTM/LTM revenue growth is -76%
Entrada Therapeutics's revenue per employee for the last fiscal year averaged $1.2M, while opex per employee averaged $0.9M for the same period.
Over next 12 months, Entrada Therapeutics's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Entrada Therapeutics's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Entrada Therapeutics and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | 63% | XXX | XXX | XXX | XXX |
| EBITDA Margin | 24% | XXX | XXX | XXX | XXX |
| EBITDA Growth | -15921% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | -52% | XXX | XXX | XXX | XXX |
| Revenue per Employee | $1.2M | XXX | XXX | XXX | XXX |
| Opex per Employee | $0.9M | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | 18% | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | 59% | XXX | XXX | XXX | XXX |
| Opex to Revenue | 78% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Entrada Therapeutics acquired XXX companies to date.
Last acquisition by Entrada Therapeutics was XXXXXXXX, XXXXX XXXXX XXXXXX . Entrada Therapeutics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was Entrada Therapeutics founded? | Entrada Therapeutics was founded in 2016. |
| Where is Entrada Therapeutics headquartered? | Entrada Therapeutics is headquartered in United States of America. |
| How many employees does Entrada Therapeutics have? | As of today, Entrada Therapeutics has 183 employees. |
| Who is the CEO of Entrada Therapeutics? | Entrada Therapeutics's CEO is Mr. Dipal Doshi. |
| Is Entrada Therapeutics publicy listed? | Yes, Entrada Therapeutics is a public company listed on NAS. |
| What is the stock symbol of Entrada Therapeutics? | Entrada Therapeutics trades under TRDA ticker. |
| When did Entrada Therapeutics go public? | Entrada Therapeutics went public in 2021. |
| Who are competitors of Entrada Therapeutics? | Similar companies to Entrada Therapeutics include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Entrada Therapeutics? | Entrada Therapeutics's current market cap is $298M |
| What is the current revenue of Entrada Therapeutics? | Entrada Therapeutics's last 12-month revenue is $161M. |
| What is the current EV/Revenue multiple of Entrada Therapeutics? | Current revenue multiple of Entrada Therapeutics is -0.4x. |
| What is the current revenue growth of Entrada Therapeutics? | Entrada Therapeutics revenue growth between 2023 and 2024 was 63%. |
| Is Entrada Therapeutics profitable? | Yes, Entrada Therapeutics is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
